IRVINE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion
pulse oximetry, today announced that all customers purchasing the Masimo
Radical-7, the company's flagship product, will now receive Desat Index 3D
Alarm as a standard feature.
Conventional pulse oximeters typically alarm based on large and isolated
drops in oxygen saturation values, known as a "desaturation". However,
published research has shown that a cycle of moderate desaturations has been
shown to precede respiratory failure in hospitalized patients(1,2). Masimo
Desat Index 3D Alarm enables advanced notification of these conditions, based
on clinician-specified severity and number of desaturations occurring in a
specified period of time.
Michael O'Reilly, MD, Masimo Executive Vice President of Medical Affairs,
stated; "When combined with the proven ability of Masimo Signal Extraction
Technology (SET) to dramatically reduce false desaturation alarms and improve
the detection of true desaturations, Masimo Desat Index 3D Alarm advances
patient care by allowing earlier intervention to prevent adverse respiratory
events."
Joe Kiani, Chairman and CEO of Masimo, stated; "Masimo has been selling
Desat Index 3D Alarm as an option for almost three years. In light of our
soon-to-be released breakthrough innovation, noninvasive and continuous
hemoglobin monitoring technology, we are pleased to now offer Desat Index 3D
Alarm as a standard feature."
(1) Continuous Pulse Oximeter Monitoring for Inapparent Hypoxemia after
Long Bone Fractures. Wong MW, Tsui HF, Yung SH, Chan KM, Cheng JC. Journal
of Trauma-Injury Infection & Critical Care. 56(2):356-362, February 2004.
(2) Occurance and Mechanisms of Sudden Oxygen Desaturation in Infants Who
Sleep Face Down. Patel AL, Paluszynska D, Harris KA, Thach BT.Pediatrics. 2003
Apr;111(4 Pt 1):e328-32.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive
blood constituent monitoring platform that can measure many blood constituents
that previously required invasive procedures. Masimo Rainbow SET continuously
and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content
(SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and
PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These forward-
looking statements are based on current expectations about future events
affecting us and are subject to uncertainties and factors, all of which are
difficult to predict and many of which are beyond our control, including:
risks related to our assumption that the addition of Desat Index 3D Alarms as
a standard feature on the Masimo Radical-7 will lead to additional device
sales, as well as other factors discussed in the "Risk Factors" section of our
quarterly report on Form 10-Q for the quarter ended June 28, 2008, filed with
the Securities and Exchange Commission on August 5, 2008. Although we believe
that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. You
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the risk factors
contained in our quarterly report on Form 10-Q for the quarter ended June 28,
2008, whether as a result of new information, future events or otherwise,
except as may be required under the federal securities laws.
Contact:
Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57, Rad-9,
Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or
registered trademarks of Masimo Corporation.
SOURCE Masimo